Parkinsons is a neurodegenerative condition. This means that cells in the brain are being lost over time. Any cure for Parkinsons is going to require some form of cell replacement therapy introducing new cells that can replace those that were lost.
Cell transplantation represents one approach to cell replacement therapy, and this week we learned that the Japanese regulatory authorities have given the green light for a new cell transplantation clinical trial to take place in Kyoto.
This new trial will involve cells derived from induced pluripotent stem cells (or IPS cells).
Intodays post we will discuss whatinduced pluripotent stem cells are, what previous research has been conducted on these cells, and what we know about the new trial.
The man in the image above is ProfShinya Yamanaka.
Hes a rockstar in the biomedical research community.
ProfYamanaka is the director ofCenter forinduced Pluripotent Stem CellResearch and Application(CiRA); and a professor at theInstitute for Frontier Medical SciencesatKyoto University.
But more importantly, in 2006 he published a research report that would quite literally change everything.
In that report, he demonstrated a method by which someonecould take a simple skin cell (called a fibroblast), grow it in cell culture for a while, and then re-programit so that it would transform into a stem cell a cell that is capable of becoming any kind of cell in the body.
The transformed cells were calledinduced pluripotent stem (IPS) cell pluripotent meaning capable of any fate.
It was an amazing feat that made the hypothetical idea of personalised medicine suddenly very possible take skin cells from anyone with a particular medical condition, turn them into whatever cell type you like, and then either test drugs on those cells or transplant them back into their body (replacing the cells that have been lost due to the medical condition).
Personalised medicine with IPS cells. Source:Bodyhacks
IPS cells are now being used all over the world, for all kinds of biomedical research. And many research groups are rushing to bring IPS cell-based therapies to the clinic in the hope of providing the long sort-after dream of personalised medicine.
This week the Parkinsons community received word that the Pharmaceuticals and Medical Devices Agency (PMDA) the Japanese regulatory agency that oversees clinical trials have agreed for researchers at Kyoto University to conduct a cell transplantation trial for Parkinsons, using dopamine neurons derived from IPS cells. And the researchers are planning to begin their study in the next month.
In todays post we are going to discuss this exciting development, but we should probably start at the beginning with the obvious question:
What exactly is an IPS cell?
New research provides some interesting insight into particular cellular functions and possibly sleep issues associated with Parkinsons.
Researchers in Belgium have recently published interesting findings that a genetic model of Parkinsons exhibits sleep issues, which are not caused by neurodegeneration, but rather neuronal dysfunction. And as a result, they were able to treat it in flies at least.
In todays post, we will review this new research and consider its implications.
I am a night owl.
One that is extremely reluctant to give up each day to sleep. There is always something else that can be done before going to bed. And I can often be found pottering around at 1 or 2am on a week night.
As a result of this foolish attitude, I am probably one of the many who live in a state of sleep deprivation.
I am a little bit nervous about doing the spoon test:
But I do understand that sleep is very important for our general level of health and well being. And as a researcher on the topic, I know that sleep complications can be a problem for people with Parkinsons.
What sleep issues are there for people with Parkinsons?
This week a group of scientists have published an article which indicates differences between mice and human beings, calling into question the use of these mice in Parkinsons disease research.
The results could explain way mice do not get Parkinsons disease, and theymay also partly explain why humans do.
In todays post we will outline the new research, discuss the results, and look at whether Levodopa treatment may (or may not) be a problem.
The humble lab mouse. Source: PBS
Much of our understanding of modern biology is derived from the lower organisms.
From yeast to snails (there is a post coming shortly on a snail model of Parkinsons disease I kid you not) and from flies to mice, a great deal of what we know about basic biology comes from experimentation on these creatures. So much in fact that many of our current ideas about neurodegenerative diseases result from modelling those conditions in these creatures.
Now say what you like about the ethics and morality of this approach, these organisms have been useful until now. And I say until now because an interesting research report was released this week which may call into question much of the knowledge we have from the modelling of Parkinsons disease is these creatures.
You see, heres the thing: Flies dont naturally develop Parkinsons disease.
Nor do mice. Or snails.
Or yeast for that matter.
So we are forcing a very un-natural state upon the biology of these creatures and then studying the response/effect. Which could be giving us strange results that dont necessarily apply to human beings. And this may explain our long history of failed clinical trials.
We work with the best tools we have, but it those tools are flawed
What did the new research report find?
This is the study:
Title: Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinsons disease Authors: Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, Santos DP, Blanz J, Obermaier CD, Strojny C, Savas JN, Kiskinis E, Zhuang X, Krger R, Surmeier DJ, Krainc D Journal: Science, 07 Sept 2017 Early online publication PMID:28882997
The researchers who conducted this study began by growing dopamine neurons a type of cell badly affected by Parkinsons disease from induced pluripotent stem (IPS) cells.
What are induced pluripotent stem cells?
Two months ago a research report was published in the scientific journal Nature and it caused a bit of a fuss in the embryonic stem cell world.
Embryonic stem (ES) cells are currently being pushed towards the clinic as a possible source of cells for regenerative medicine. But this new report suggested that quite a few of the embryonic stem cells being tested may be carrying genetic variations that could be bad. Bad as in cancer bad.
In this post, I will review the study and discuss what it means for cell transplantation therapy for Parkinsons disease.
For folks in the stem cell field, the absolute go-to source for all things stem cell related isProf Paul Knoepflers blog The Niche. From the latest scientific research to exciting new stem cell biotech ventures (and even all of the regulatory changes being proposed in congress), Pauls blog is a daily must read for anyone serious about stem cell research. He has his finger on the pulse and takes the whole field very, very seriously.
Prof Paul Knoepfler during his TED talk.Source: ipscell
For a long time now, Paul has been on a personal crusade. Like many others in the field (including yours truly), he has been expressing concern about the unsavoury practices of the growing direct-to-consumer, stem cell clinic industry. You may have seen him mentioned in the media regarding this topic (such as this article).
The real concern is that while much of the field is still experimental, many stem cell clinics are making grossly unsubstantiated claims to draw in customers. From exaggerated levels of successful outcomes (100% satisfaction rate?) all the way through to talking about clinical trials that simply do not exist.The industry is badly (read: barely) regulated which is ultimately putting patients at risk (one example: three patients were left blind after undergoing an unproven stem cell treatment click here to read more on this).
While the stem cell research field fully understands and appreciates the desperate desire of the communities affected by various degenerative conditions, there has to be regulations and strict control standards that all practitioners must abide by. And first amongst any proposed standards should be that the therapy has been proven to be effective for a particular condition in independently audited double blind, placebo controlled trials. Until such proof is provided, the sellers of such products are simply preying on the desperation of the people seeking these types of procedures.
Last weekscientists in Sweden published researchdemonstrating a method by which the supportive cells of the brain (called astrocytes) can be re-programmed into dopamine neurons in the brain of a live animal!
It was a reallyimpressive trick and it could have major implications for Parkinsons disease.
In todays post is a long read, but in it we will review the research leading up to the study, explain the science behindthe impressive feat, and discuss where things go from here.
Different types of cells in the body. Source: Dreamstime
In your body at this present moment in time, there is approximately 40 trillion cells (Source).
The vast majority of those cells have developedinto mature types of cell and they are undertaking veryspecific functions. Muscle cells, heart cells, brain cells all working together in order to keep you verticaland ticking.
Now, once upon a time we believed that the maturation (or the more technical term: differentiation) of a cell was a one-way street. That is to say, once acellbecame what it was destined to become, there was no going back. This was biological dogma.
Then aguy in Japan did something rather amazing.
Who is he and what did he do?
This is ProfShinya Yamanaka:
ProfShinya Yamanaka. Source: Glastone Institute
Hes a rockstar in the scientific research community.
ProfYamanaka is the director of Center for induced Pluripotent Stem Cell Research and Application(CiRA); and a professor at theInstitute for Frontier Medical Sciences at Kyoto University.
But more importantly, in 2006 he published a research reportdemonstrating how someonecould take a skin cell and re-programit so that was now a stem cell capable of becoming any kind of cell in the body.
Heres the study:
Title: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Authors: Takahashi K, Yamanaka S. Journal: Cell. 2006 Aug 25;126(4):663-76. PMID: 16904174 (This article is OPEN ACCESS if you would like to read it)
Shinya Yamanakas team started with the hypothesis that genes which are important to the maintenance of embryonic stem cells (the cells that give rise to all cells in the body) might also be able to cause an embryonic state in mature adult cells. They selected twenty-four genes that had been previously identified as important in embryonic stem cells to test this idea. They used re-engineered retroviruses to deliver these genes to mouse skin cells. The retroviruses were emptied of all their disease causing properties, and could thus function as very efficient biological delivery systems.
The skin cells were engineered so that only cells in which reactivation of the embryonic stem cells-associated gene, Fbx15, would survive the testing process. If Fbx15 was not turned on in the cells, they would die. When the researchers infected the cells with all twenty-four embryonic stem cells genes, remarkably some of the cells survived and began to divide like stem cells.
In order to identify the genes necessary for the reprogramming, the researchers began removing one gene at a time from the pool of twenty-four. Through this process, they were able to narrow down the most effective genes to justfour: Oct4, Sox2, cMyc, and Klf4, which became known as the Yamanaka factors.
This new type of cell is called an induced pluripotent stem (IPS) cell pluripotent meaning capable of any fate.
The discovery of IPS cells turned biological dogma on its head.
And in acknowledgement of this amazing bit of research, in 2012 ProfYamanaka and Prof John Gurdon (University of Cambridge)were awarded the Nobel prize for Physiology and Medicinefor the discovery that mature cells can be converted back to stem cells.
Prof Yamanaka and Prof Gurdon. Source: UCSF
Prof Gurdon achieved the feat in 1962 when he removed the nucleus of a fertilised frog egg cell and replaced it with the nucleus of a cell taken from a tadpoles intestine. The modified egg cell then grew into an adult frog! This fascinatingresearchproved that the mature cell still contained the genetic information needed to form all types of cells.
EDITORS NOTE: We do not want to be accused of taking anything away from Prof Gurdons contribution to this field (which was great!) by not mentioning his efforts here. For the sake of saving time and space, we are focusing onProf Yamanakas research as it is more directly related to todays post.
Making IPS cells. Source: learn.genetics
- Ncardia inks $60M funding deal to expand discovery and commercial production services for stem cells - FierceBiotech - November 22nd, 2021
- ElevateBio Supercharges Gene Editing and Therapeutic Product Development Capabilities Through Acquisition of Life Edit Therapeutics - Yahoo Finance - October 28th, 2021
- ReNeuron enters cancer therapy collaboration with UCL - ShareCast - October 28th, 2021
- Shah on the Potential Utility of NK Cells in Multiple Myeloma - OncLive - October 28th, 2021
- Exacis Biotherapeutics Announces Strategic Partnership With CCRM For Specialty Manufacturing Of Services And Investment For Development Of... - October 28th, 2021
- CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform - WWNY - October 16th, 2021
- ASU professor researches origins of Alzheimers to find a cure - Eight, Arizona PBS - October 16th, 2021
- Personalized Cell Therapy Market Size Worth US$ 53.8 Billion With a CAGR of 23.5% By 2028 Otterbein 360 - Otterbein 360 - October 16th, 2021
- Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777) - Yahoo Finance - October 16th, 2021
- Wolter Earns Young Investigator Award | Newsroom - UNC Health and UNC School of Medicine - October 16th, 2021
- NIH awards nearly $2M to Huebsch for study | The Source - Washington University in St. Louis Newsroom - August 31st, 2021
- Shoreline Launches with $4 Billion in Partnerships PharmaLive - PharmaLive - August 31st, 2021
- Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004 - GlobeNewswire - August 31st, 2021
- Roslin Tech in multi-million bid to fund sustainable food - HeraldScotland - August 31st, 2021
- Global Induced Pluripotent Stem Cells Market Industry Analysis, Post COVID-19 Impact, Emerging Trends, Business Growth by 2027||Fate Therapeutics,... - July 22nd, 2021
- Bayer's BlueRock Therapeutics gains FDA fast track for Parkinson's disease cell therapy - PMLiVE - July 22nd, 2021
- Global Induced Pluripotent Stem Cell (iPSC) Market to Reach $2.3 Billion by 2026 - PRNewswire - July 7th, 2021
- Impact of NK cell-based therapeutics for Lung Cancer Therapy | BTT - Dove Medical Press - July 7th, 2021
- Caribou eyes $100M IPO as it aims off-the-shelf CAR-Ts at the clinic - FierceBiotech - July 7th, 2021
- Genexine, Toolgen to co-develop CAR-NK cell gene therapy - Korea Biomedical Review - July 7th, 2021
- Reversal of biological age detected in mouse and human embryos - BioNews - July 7th, 2021
- Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase - GlobeNewswire - June 25th, 2021
- Univ. of Washington and Sana researchers use gene editing to prep stem cells for heart repair - GeekWire - June 25th, 2021
- Ubiquitination is essential for recovery of cellular activities after heat shock - Science Magazine - June 25th, 2021
- The CCL2-CCR2 astrocyte-cancer cell axis in tumor extravasation at the brain - Science Advances - June 25th, 2021
- Pharmacogenomic approach to cure the pain of the 'burning man' - Lab + Life Scientist - June 25th, 2021
- The Stem Cell Assay Market To Grow Through Mergers Amongst Market Participants The Courier - The Courier - June 25th, 2021
- Accelerated Biosciences' Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and... - May 15th, 2021
- Study Models the Effect of Herpes Infection on Fetal Brain Development - Pharmacy Times - May 15th, 2021
- Induced Pluripotent Stem Cells Market is set for Lucrative Growth | Top Companies Thermo Fisher Scientific Inc., FUJIFILM Corporation, KSU | The... - May 15th, 2021
- Stem Cell Therapy Market by Type, Therapeutic Application and Cell Source - Global Forecasts to 2026 - ResearchAndMarkets.com - Business Wire - May 15th, 2021
- Global Induced Pluripotent Market Showing Impressive Growth by 2027||Thermo Fisher Scientific; Cell Applications, Inc.; Axol Bioscience Ltd.;... - May 15th, 2021
- Global Induced Pluripotent Stem Cells Market 2020 Top Manufactures, Growth Opportunities and Investment Feasibility 2025 The Courier - The Courier - May 3rd, 2021
- Stem Cell Therapy Market worth $401 million by 2026 - Exclusive Report by MarketsandMarkets - PRNewswire - May 3rd, 2021
- Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting - GlobeNewswire - May 3rd, 2021
- Induced Pluripotent Stem Cells (iPSCs) Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top Players... - May 3rd, 2021
- Induced Pluripotent Stem Cells (iPSCs) Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Fujifilm Holding Corporation (CDI),... - May 3rd, 2021
- A New CRISPR Tool Flips Genes On and Off Like a Light Switch - Singularity Hub - May 3rd, 2021
- Stem Cell Characterization Kits Market Report 2021 by Global Key Players, Types, Applications, Countries, Size, Forecast to 2027 Good News Gum - Good... - May 3rd, 2021
- Induced Pluripotent Stem Cells Market Growth Opportunities, Analysis and Forecasts Report 2020-2026 with key players position (Fujifilm Holding... - February 17th, 2021
- Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells - BioSpace - February 17th, 2021
- Can we freeze them? Yes we can, says Nkarta - Vantage - February 17th, 2021
- Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas... - February 17th, 2021
- Induced Pluripotent Stem Cells Market Growth, Competitive Landscape, Research Methodology, Business Opportunities, Statistics and Industry Analysis... - February 17th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy f - PharmiWeb.com - February 4th, 2021
- Breakthrough stem cell therapy may reverse life-threatening conditions in dogs - Study Finds - February 4th, 2021
- SLAS Technology Special Collection on Artificial Intelligence in Process Automation Available Now - Newswise - February 4th, 2021
- Exacis Biotherapeutics Announces Key Addition To Its Executive Leadership Team With Dirk Huebner MD Joining As Chief Medical Officer - PRNewswire - February 4th, 2021
- Induced Pluripotent Stem Cells Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis And Forecast... - February 4th, 2021
- Money on the Move: January 27 February 2 - BioSpace - February 4th, 2021
- Poultry Healthcare Products Market Share, Growth, Statistics, by Application, Production, Revenue & Forecast to 2025 - AlgosOnline - January 27th, 2021
- Impact Of Covid 19 On Stem Cells Industry 2020 Market Challenges, Business Overview And Forecast Research Study 2026 Murphy's Hockey Law - Murphy's... - January 27th, 2021
- SREBP1 suppresses the differentiation and epithelial function of hiPSC-derived endothelial cells by inhibiting the microRNA199b-5p pathway - DocWire... - January 25th, 2021
- Induced Pluripotent Stem Cells Market Segmentation and Analysis by Latest Trends, Development and Growth by Trending Regions 2020 with key players... - January 25th, 2021
- Induced Pluripotent Stem Cells (iPSCs) Market to Witness Massive Growth During 2021-2027 | Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo... - January 25th, 2021
- Hands across the water as bio bonds stand test of time | Business Weekly - Business Weekly - January 25th, 2021
- Exercise mimetics and JAK inhibition attenuate IFN-induced wasting in engineered human skeletal muscle - Science Advances - January 25th, 2021
- Can Science Save the Northern White Rhino? - Freethink - January 25th, 2021
- Induced Pluripotent Stem Cells Market to Grow with an Impressive CAGR - Farming Sector - January 9th, 2021
- Accelerating cell-based therapies by providing safe therapeutic MSC products - BioSpace - January 9th, 2021
- Exacis Biotherapeutics Announces Its Launch and mRNA Technology In-Licensing For Targeted CAR-NK And CAR-T Cell Cancer Therapies | DNA RNA and Cells |... - January 9th, 2021
- Environmental Factor - January 2021: Intramural Papers of the Month - Environmental Factor Newsletter - January 9th, 2021
- Global Induced Pluripotent Stem Cells Market To Witness Huge Gains Over 2020-2026 - Factory Gate - December 28th, 2020
- Exosomes act as messengers and decoys to save healthy cells from viral infection - Massive Science - December 28th, 2020
- Scientists have restored youth to aging eyes in mice - Massive Science - December 21st, 2020
- Top Technical Advances of 2020 - The Scientist - December 21st, 2020
- A new psychedelic drug gives psychiatric benefits without causing hallucinations - Massive Science - December 21st, 2020
- I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic - PRNewswire - December 17th, 2020
- Network of Genes Involved in Congenital Heart Disease Identified - Technology Networks - December 17th, 2020
- Global Induced Pluripotent Market 2020-26 Steering Forces Heading Towards Impressive CAGR With CELGENE CORPORATION; Astellas Pharma Inc.; Thermo... - December 17th, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market Expectable to Exceed Global Market Revenue, Size, Segments and Market Competition Trend to... - December 14th, 2020
- Evotec and Sartorius Partner with Start-Up Curexsys on IPSC-Based Therapeutic Exosome Approach - BioSpace - December 9th, 2020
- Multiple gene edits and computer simulations could help treat rare genetic diseases - University of Wisconsin-Madison - December 9th, 2020
- Cytovia Therapeutics announces plans to initiate in 2021 Clinical Development of Universal iPSC NK Cell Therapy for Hematological and Solid Tumors -... - December 9th, 2020
- Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma - GlobeNewswire - December 9th, 2020
- Constantly Growing Applications and Innovations to Push Sales of Amniotic Membrane Market Up To ~US$2.4 Bn by 2027, Observes TMR - PRNewswire - December 9th, 2020
- Tulane researcher shows enhanced therapeutic stem cell migration improves neurodegenerative disease - News from Tulane - December 8th, 2020
- Researchers restore lost sight in mice, offering clues to reversing aging - Science Magazine - December 8th, 2020
- Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma | DNA RNA and Cells... - December 8th, 2020
- Bayer and Atara Biotherapeutics in CAR T-cell therapy deal - BioPharma-Reporter.com - December 8th, 2020